NO980556L - Fremgangsmåte for reduksjon av mengden eksogent insulin administrert til en pasient med ikke-insulinavhenig diabetes mellitus - Google Patents

Fremgangsmåte for reduksjon av mengden eksogent insulin administrert til en pasient med ikke-insulinavhenig diabetes mellitus

Info

Publication number
NO980556L
NO980556L NO980556A NO980556A NO980556L NO 980556 L NO980556 L NO 980556L NO 980556 A NO980556 A NO 980556A NO 980556 A NO980556 A NO 980556A NO 980556 L NO980556 L NO 980556L
Authority
NO
Norway
Prior art keywords
insulin
patient
amount
reducing
diabetes mellitus
Prior art date
Application number
NO980556A
Other languages
English (en)
Norwegian (no)
Other versions
NO980556D0 (no
Inventor
Randall W Whitcomb
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO980556D0 publication Critical patent/NO980556D0/no
Publication of NO980556L publication Critical patent/NO980556L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO980556A 1995-08-10 1998-02-09 Fremgangsmåte for reduksjon av mengden eksogent insulin administrert til en pasient med ikke-insulinavhenig diabetes mellitus NO980556L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US209895P 1995-08-10 1995-08-10
PCT/US1996/012430 WO1997005875A2 (fr) 1995-08-10 1996-07-29 Procede permettant de reduire la quantite d'insuline exogene administree a un patient souffrant de diabete sucre non-insulinodependant

Publications (2)

Publication Number Publication Date
NO980556D0 NO980556D0 (no) 1998-02-09
NO980556L true NO980556L (no) 1998-02-09

Family

ID=21699238

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980556A NO980556L (no) 1995-08-10 1998-02-09 Fremgangsmåte for reduksjon av mengden eksogent insulin administrert til en pasient med ikke-insulinavhenig diabetes mellitus

Country Status (15)

Country Link
EP (1) EP0851757A2 (fr)
JP (1) JPH11510508A (fr)
KR (1) KR19990036290A (fr)
CN (1) CN1192683A (fr)
AU (1) AU724989B2 (fr)
BG (1) BG102235A (fr)
CA (1) CA2221241A1 (fr)
CZ (1) CZ32998A3 (fr)
EA (1) EA199800177A1 (fr)
HU (1) HUP9802543A2 (fr)
IL (1) IL122191A0 (fr)
NO (1) NO980556L (fr)
NZ (1) NZ313874A (fr)
SK (1) SK16498A3 (fr)
WO (1) WO1997005875A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
GB2335597A (en) * 1998-03-27 1999-09-29 Glaxo Group Ltd Stereoisomers of Troglitazone in the Treatment of Diabetes
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
HUP9802543A2 (hu) 1999-07-28
CN1192683A (zh) 1998-09-09
EA199800177A1 (ru) 1998-10-29
WO1997005875A2 (fr) 1997-02-20
NO980556D0 (no) 1998-02-09
CA2221241A1 (fr) 1997-02-20
BG102235A (en) 1998-09-30
CZ32998A3 (cs) 1998-10-14
IL122191A0 (en) 1998-04-05
EP0851757A2 (fr) 1998-07-08
AU6641196A (en) 1997-03-05
JPH11510508A (ja) 1999-09-14
SK16498A3 (en) 1999-03-12
KR19990036290A (ko) 1999-05-25
AU724989B2 (en) 2000-10-05
WO1997005875A3 (fr) 1997-03-27
NZ313874A (en) 2000-09-29

Similar Documents

Publication Publication Date Title
NO931267D0 (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
FI842915A0 (fi) Farmaceutiskt medel foer behandling av diabetes.
EA200000041A1 (ru) Способ лечения диабета тиазолидиндионом и метформином
DK0536226T3 (fr)
AU2001294602A1 (en) Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
EP0664703A1 (fr) METHODES POUR LUTTER CONTRE LA PNEUMONIE A $i(PNEUMOCYSTIS CARINII) ET COMPOSES UTILES A CET EFFET
RU2000100346A (ru) Способы лечения ожирения
AU8244591A (en) Calcitonin-containing emulsion for nasal administration
NO20083276L (no) Behandling av diabetes med tiazolidindion og sulfonylurea
NO980556L (no) Fremgangsmåte for reduksjon av mengden eksogent insulin administrert til en pasient med ikke-insulinavhenig diabetes mellitus
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
BR9810186A (pt) Tratamento de diabete com tiazolidinadiona e inibidor de alfa-glicosidade
MX9709958A (es) Un metodo para reducir la cantidad de insulina exogena administrada a un paciente que tenga diabetes melitus dependiente de insulina.
BG104139A (en) Diabetes treatment with thizolidindion and sulphonylurea
CA2145501A1 (fr) Methode pour le traitement ou la prevention de l'obesite
AU7718796A (en) 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus
NO20016301L (no) Terapeutiske midler
NO950599L (no) Fremgangsmåte for inhibering av HIV-replikasjon ved anvendelse av IL-4
RU96115219A (ru) Способ лечения больных сахарным диабетом

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application